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Introduction
Chronic nonbacterial osteomyelitis (CNO) is the most
common autoinflammatory bone disorder in childhood
(1). Diagnostic information is provided by TC-99 bone
scintigraphy (BS) and/or whole body MRI. Non-steroidal
anti-inflammatory drugs (NSAIDs), glucocorticoids,
bisphosphonates and tumour necrosis factor inhibitors
have been used until now with variable response (2).
Objectives
To describe clinical, biological and radiological response
to treatment with anakinra in patients with CNO refrac-
tory to NSAIDs and bisphosphonates.
Materials and methods
Seven patients (4 females and 3 males) with refractory
CNO were treated with anakinra for at least 6 months in
our institution. Response to treatment was evaluated
assessing clinical manifestations (pain, local swelling, func-
tional impairment), laboratory findings (C-reactive protein
(CRP)), erythrocyte sedimentation rate (ESR)) and serum
amyloid A level (SAA))) and number of bone lesions on
TC-99 BS at the start of treatment and at 6 months.
Results
The median age at diagnosis and before starting anakinra
was 9.7 years (IQR 7.8-14.7) and 13.3 years (IQR 8.0-15.9)
respectively. All were treated with NSAIDs and bispho-
sphonates as first-line therapy. Glucocorticoid therapy was
required in one patients with concomitant recurrent fever
and pleural effusion. These patients did not respond satis-
factorily and anakinra (2 mg/kg/day) was started. At the
start of treatment 7/7 patients (100%) had pain, 3/7 (43%)
local swelling and 5/7 (71%) functional impairment; at
6 months of follow up 6/7 patients (86%) were completely
asymptomatic, with one patient complaining of arthralgia.
Before starting anakinra the median CRP, ESR and SAA
were 2.7 mg/dl (IQR 1.7-4.9) 26 mm/h (IQR 12-46) and
53 mg/dl (IQR 27-112); at 6 months 5/7 patients (71%)
normalized CRP, ESR and SAA; 2/7 had a decrease in
inflammatory markers. Before anakinra 59 bone lesions
were detected on TC-99 BS. After 6 months of therapy
24/59 lesions (40%) had completely resolved, 1/59 lesions
(2%) had partially improved and 29/59 lesions (49%)
remained stable. In two patients with persistent high bio-
logical inflammatory markers, new lesions (14) developed
during treatment.
Conclusion
Our data suggest that anakinra appears effective in CNO
in controlling symptoms and laboratory findings; subclini-
cal bone inflammation was still detectable by BS after
6 months of treatment. Long-term follow-up studies with
a larger number of patients are needed.
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